- Liminatus Pharma posted a net loss of **$1.41 million** for the quarter ended June 30, 2026, versus net income of **$113,287**. - Operating loss widened **23%** to **$1.38 million**, as research and development expense rose to **$600,000** from none. - General and administrative costs fell **30%** to **$778,908**, on lower accounting and legal expenses tied to the prior-year business combination. - Cash totaled **$3.02 million** at June 30, 2026; accumulated deficit stood at **$41.4 million**. - The company completed a February public offering raising about **$3.44 million** in net proceeds; a June warrant inducement added about **$1.62 million**.
LIMN•LIMN•LIMN•LIMN•
